We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Foreign investment in Mexico's drug sector should continue to rise, as sales start to pick up the pace and the country improves its intellectual property and pricing environment.
Inyx, Inc. (OTC Bulletin Board: IYXI -- News), a specialty pharmaceutical company with a focus on niche drug delivery technologies and products, today reported updated financial guidance for 2005 and 2006.
Applied Pharma Research (APR), a Swiss-based R&D firm that specializes in enhancing drug delivery, and ProEthic Pharmaceuticals Inc., announced today that APR has granted an exclusive license to ProEthic to develop and market two fast-acting formulations of diclofenac potassium in the U.S. and Canada.
Ranbaxy Laboratories Ltd. on Tuesday announced its entry into the Italian pharmaceutical market with the launch of Ranbaxy Italia S.P.A., a wholly-owned subsidiary of the company.
Pfizer Inc said today that it has received European Mutual Recognition Procedure (MRP) approval to market Aromasin(R) (exemestane tablets) for a new indication, adjuvant treatment of estrogen receptor positive invasive early breast cancer following two-to-three years of initial adjuvant tamoxifen therapy in postmenopausal women.
The Swiss authorities have approved Roche and GlaxoSmithKline's Bonviva for the treatment of postmenopausal osteoporosis, providing the foundations for approval in other countries.